Samsung Biologics, APRINOIA Enter mAb Pact

Samsung Biologics entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supranuclear Palsy and Alzheimer's disease, which are all currently incurable.

The candidate was selected from APRINOIA's antibody platform to target specific pathological tau aggregates with novel conformation-dependent epitopes, aiming to slow down disease progression.   

Samsung will provide the full scope of the candidate product's development phase from cell line development, process development, cGMP manufacturing to IND filing support.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.